Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II)

JACC: Cardiovascular Interventions

Volumn 8, Issue 7, 2015, Pages 889-899

  Sen, Hanim ^a   Lam, Ming Kai ^a   Löwik, Marije M ^a   Danse, Peter W ^b   Jessurun, Gillian A J ^c   Van Houwelingen, K Gert ^a   Anthonio, Rutger L ^c   Tjon Joe Gin, R Melvyn ^b   Hautvast, Raymond W M ^d   Louwerenburg, J W ^a   De Man, Frits H A F ^a   Stoel, Martin G ^a   Van Der Heijden, Liefke C ^a   Linssen, Gerard C M ^e   Ijzerman, Maarten J ^f   Tandjung, Kenneth ^a   Doggen, Carine J M ^f   Von Birgelen, Clemens ^a,b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c Scheper Ziekenhuis   (Netherlands)

^d Location Alkmaar   (Netherlands)

^e Hospital Group Twente   (Netherlands)

^f UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

all comer all comers; DES; drug eluting stents; EES; percutaneous coronary intervention; Promus Element platinum chromium everolimus eluting stent; randomized clinical trial; Resolute Integrity cobalt chromium zotarolimus eluting stent; ZES

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; EVEROLIMUS ELUTING CORONARY STENT; EXERCISE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVASCULARIZATION; THORAX PAIN; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ANGINA PECTORIS; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DEVICES; DRUG ELUTING STENT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTHESIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; TIME; TREATMENT OUTCOME;

CARDIOVASCULAR AGENT; EVEROLIMUS; POLYMER; RAPAMYCIN; ZOTAROLIMUS;

AGED; ANGINA PECTORIS; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SINGLE-BLIND METHOD; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931561440     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.01.033     Document Type: Article

References (32)

1. G.G. Stefanini, and D.R. Holmes Jr. Drug-eluting coronary-artery stents N Engl J Med 368 2013 254 265
2. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
3. C. von Birgelen, M.W. Basalus, and K. Tandjung A randomized controlled trial in second-generation zotarolimus-eluting resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial J Am Coll Cardiol 59 2012 1350 1361
4. C. von Birgelen, H. Sen, and M.K. Lam Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial Lancet 383 2014 413 423
5. K.W. Park, S.H. Kang, and H.J. Kang A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-Platelet Regimen), a randomized, controlled, noninferiority trial J Am Coll Cardiol 63 2014 2805 2816
6. B. Raungaard, L.O. Jensen, and H.H. Tilsted Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting bodegraven-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial Lancet 385 2015 1527 1535
7. Stone GW. Demonstration of clinical superiority with a bioresorbable vascular scaffold: The ABSORB III + IV Clinical Trial Program. Paper presented at: EuroPCR; May 20, 2014; Paris, France.
8. R. Jaworski, E.A. Jankowska, P. Ponikowski, and W. Banasiak Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study Pol Arch Med Wewn 122 2012 599 607
9. A.C. Yeung, M.B. Leon, and A. Jain Clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial J Am Coll Cardiol 57 2011 1778 1783
10. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
11. L.O. Jensen, P. Thayssen, and H.S. Hansen Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Circulation 125 2012 1246 1255
12. G.W. Stone, A. Rizvi, and W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
13. G.W. Stone, P.S. Teirstein, and I.T. Meredith A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial J Am Coll Cardiol 57 2011 1700 1708
14. I.T. Meredith, P.S. Teirstein, and A. Bouchard Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM trial) Am J Cardiol 113 2014 1117 1123
15. P.D. Williams, M.A. Mamas, and K.P. Morgan Longitudinal stent deformation: a retrospective analysis of frequency and mechanisms EuroIntervention 8 2012 267 274
16. M.A. Mamas, and P.D. Williams Longitudinal stent deformation: Insights on mechanisms, treatments and outcomes from the food and drug administration manufacturer and user facility device experience database EuroIntervention 8 2012 196 204
17. K. Tandjung, M.W. Basalus, and H. Sen DUrable polymer-based sTent CHallenge of promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a dutch all-comers population Am Heart J 163 2012 557 562
18. K. Tandjung, H. Sen, and M.K. Lam Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial J Am Coll Cardiol 61 2013 2406 2416
19. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
20. P. Vranckx, D.E. Cutlip, and R. Mehran Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. addendum to the historical MI definitions used in stent studies EuroIntervention 5 2010 871 874
21. R.G. Newcombe Interval estimation for the difference between independent proportions: comparison of eleven methods Stat Med 17 1998 873 890
22. S.J. Pocock, R.A. Henderson, and A.F. Rickards Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery Lancet 346 1995 1184 1189
23. M.J. Sculpher, P. Seed, and R.A. Henderson Health service costs of coronary angioplasty and coronary artery bypass surgery: the randomised intervention treatment of angina (RITA) trial Lancet 344 1994 927 930
24. P.W. Serruys, P. de Jaegere, F. Kiemeneij Benestent Study Group A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease N Engl J Med 331 1994 489 495
25. D.L. Fischman, M.B. Leon, and D.S. Baim A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators N Engl J Med 331 1994 496 501
26. R. Hill, A. Bagust, and A. Bakhai Coronary artery stents: A rapid systematic review and economic evaluation Health Technol Assess 8 2004 iii, iv, 1-242
27. M.S. Abdallah, K. Wang, and E.A. Magnuson Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial JAMA 310 2013 1581 1590
28. D.J. Cohen, B. Van Hout, and P.W. Serruys Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery N Engl J Med 364 2011 1016 1026
29. W.E. Boden, R.A. O'Rourke, and K.K. Teo Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503 1516
30. M.A. Hlatky, D.B. Boothroyd, and D.M. Bravata Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: A collaborative analysis of individual patient data from ten randomised trials Lancet 373 2009 1190 1197
31. J.A. Spertus, J.A. Winder, and T.A. Dewhurst Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease J Am Coll Cardiol 25 1995 333 341
32. P.J. Edwards, I. Roberts, and M.J. Clarke Methods to increase response to postal and electronic questionnaires Cochrane Database Syst Rev 3 2009 MR000008